The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors
Open Access
- 21 November 2011
- journal article
- Published by Springer Nature in Health Economics Review
- Vol. 1 (1) , 18
Abstract
This study provides an overview of policy measures targeting pharmaceutical expenditure in Europe and analyses their impact on originator pharmaceutical prices. Panel data methods are used to examine the market of ACE Inhibitors in six European countries (Denmark, France, Germany, Netherlands, Sweden, United Kingdom) over period 1991-2006. We find that although some measures are effective in reducing originator prices, others appear to have an insignificant effect. Results suggest that supply side measures such as mandatory generic substitution, regressive pharmacy mark-ups and claw-backs are effective in reducing pharmaceuticals prices. Results are not as strong for demand side measures. Profit controls and the use of cost-effectiveness analysis appear to have a negative effect on prices, while results on reference pricing are inconclusive. Findings also indicate that, although originator prices are not immediately affected by generic entry, they may be influenced by changes in generic prices post patent expiry.Keywords
This publication has 24 references indexed in Scilit:
- Determinants of branded prescription medicine prices in OECD countriesHealth Economics, Policy and Law, 2011
- PHP80 EFFECTS OF REFERENCE PRICING AND TENDER CONTRACTS IN GERMANYValue in Health, 2010
- Competition in off-patent drug markets: Issues, regulation and evidenceEconomic Policy, 2008
- Influence of mandatory generic substitution on pharmaceutical sales patterns: a national study over five yearsBMC Health Services Research, 2008
- Pharmaceutical Price Controls and Entry StrategiesReview of Economics and Statistics, 2007
- Examining the link between price regulation and pharmaceutical R&D investmentHealth Economics, 2004
- Price Competition in Pharmaceuticals: The Case of Anti‐infectivesEconomic Inquiry, 2004
- A Simple Model of Pharmaceutical Price DynamicsThe Journal of Law and Economics, 2003
- Unintended effects of a cost-containment policy: Results of a natural experiment in GermanySocial Science & Medicine, 1997
- Returns to R&D on new drug introductions in the 1980sJournal of Health Economics, 1994